BriaCell Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is August - July.

Millions USD. Fiscal year is Aug - Jul.

Year Ending	TTM	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021	Jul 31, 2020	Jul 31, 2019	2018
Net Income	-6.04	-20.3	-26.84	-13.82	-3.1	-3.63	Upgrade
Depreciation & Amortization	0.02	0.02	0.02	0.02	0.01	0.01	Upgrade
Share-Based Compensation	1.96	2.19	3.07	1.97	0	0.04	Upgrade
Other Operating Activities	-26.95	-5.65	11.26	4.08	2.11	0.39	Upgrade
Operating Cash Flow	-31.01	-23.74	-12.48	-7.75	-0.97	-3.19	Upgrade
Acquisitions	-0.23	0	0	0	0	0	Upgrade
Change in Investments	0	0	0	0	0	0.84	Upgrade
Investing Cash Flow	-0.23	0	0	0	0	0.84	Upgrade
Share Issuance / Repurchase	4	3.95	-3.66	65.33	0.89	1.95	Upgrade
Debt Issued / Paid	0	0	0	-0.33	0.02	-0.07	Upgrade
Other Financing Activities	-	-	-0.08	-	-	-	Upgrade
Financing Cash Flow	4	3.95	-3.74	65	0.9	1.88	Upgrade
Net Cash Flow	-27.23	-19.79	-16.23	57.25	-0.07	-0.48	Upgrade
Free Cash Flow	-31.01	-23.74	-12.48	-7.75	-0.97	-3.19	Upgrade
Free Cash Flow Per Share	-1.94	-1.52	-0.81	-1.72	-1.36	-5.51	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).